OTC · IMVIF
IMV Inc.
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
Loading market information…
OTC · BGMD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BG Medicine, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BG Medicine, Inc. is dedicated to the development and commercialization of diagnostic products aimed at guiding patient care for individuals in the United States afflicted with heart failure and related conditions. Its product portfolio includes the BGM Galectin-3 Test, an in vitro diagnostic solution that quantifies galectin-3 levels in blood serum or plasma using an enzyme-linked immunosorbent assay (ELISA) on a microtiter plate platform. Additionally, the company provides the CardioSCORE Test, a multi-analyte, biomarker-based blood test designed to assess the short-term risk of atherothrombotic cardiovascular events, such as myocardial infarction (heart attack) and ischemic stroke. BG Medicine maintains licensing, development, and commercialization agreements with major partners like Abbott Laboratories, bioMérieux SA, Siemens Healthcare Diagnostics Inc., and Alere Inc., specifically for automated versions of its galectin-3 test. Furthermore, it has forged a strategic alliance with Abbott Laboratories to jointly develop and market galectin-3 assay kits, along with their corresponding control kits and calibrators. Founded in 2000, the company was initially known as Beyond Genomics, Inc., before rebranding to BG Medicine, Inc. in October 2004. Its corporate headquarters are located in Waltham, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:46 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.00$0.00 (0.0%)
IMV Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
BIMI International Medical Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
FusionPharm, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Bionik Laboratories Corp.: Healthcare · Medical - Care Facilities.
$0.00$0.00 (0.0%)
PrimeCare Systems, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Millennium Sustainable Ventures Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.0% below the high.
$0.00$0.00 (0.0%)
American Medical Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
DMK Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 90.0% below the high.
